Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Karyopharm Therapeutics (KPTI) Operating Margin (2016 - 2025)

Karyopharm Therapeutics' Operating Margin history spans 14 years, with the latest figure at 93.03% for Q4 2025.

  • For Q4 2025, Operating Margin rose 19545.0% year-over-year to 93.03%; the TTM value through Dec 2025 reached 28.18%, up 5406.0%, while the annual FY2025 figure was 28.18%, 5406.0% up from the prior year.
  • Operating Margin reached 93.03% in Q4 2025 per KPTI's latest filing, up from 34.56% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 93.03% in Q4 2025 to a low of 225.16% in Q1 2021.
  • Average Operating Margin over 5 years is 85.0%, with a median of 86.07% recorded in 2022.
  • Peak YoY movement for Operating Margin: plummeted -13805bps in 2022, then surged 19545bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 37.19% in 2021, then crashed by -371bps to 100.86% in 2022, then dropped by -11bps to 112.03% in 2023, then increased by 9bps to 102.42% in 2024, then soared by 191bps to 93.03% in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Operating Margin are 93.03% (Q4 2025), 34.56% (Q3 2025), and 64.3% (Q2 2025).